NCT07476027 2026-03-17
Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Not yet recruiting
Clinical Trials
19 trialsNCT03422731 2026-03-16
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
City of Hope Medical Center
Phase EARLY_PHASE1 Recruiting
NCT05294367 2026-03-16
Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma
Mayo Clinic
Phase EARLY_PHASE1 Recruiting
NCT07428707 2026-03-13
Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
National Institutes of Health Clinical Center (CC)
Phase EARLY_PHASE1 Recruiting
NCT06235281 2026-02-27
PLIGHT
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Suspended
NCT07429461 2026-02-24
Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia
Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT03445858 2026-02-18
Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults
Children's Hospital Medical Center, Cincinnati
Phase EARLY_PHASE1 Completed
NCT04512716 2026-02-17
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT05093335 2026-02-05
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT05800405 2026-02-04
Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
City of Hope Medical Center
Phase EARLY_PHASE1 Recruiting
NCT04161248 2026-02-02
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Canadian Cancer Trials Group
Phase EARLY_PHASE1 Recruiting
NCT05921253 2026-01-26
OU-SCC-NCAN
University of Oklahoma
Phase EARLY_PHASE1 Recruiting
NCT06662227 2026-01-20
Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors
Wondercel Biotech (ShenZhen)
Phase EARLY_PHASE1 Recruiting
NCT07349849 2026-01-20
Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies
Xinqiao Hospital of Chongqing
Phase EARLY_PHASE1 Recruiting
NCT06765876 2026-01-12
UHKT-CAR123-01
Institute of Hematology and Blood Transfusion, Czech Republic
Phase EARLY_PHASE1 Recruiting
NCT07335094 2026-01-12
A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lymphoblastic Leukemia/Lymphoma Who Are Intolerant to Intensive Chemotherapy
Zhujiang Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT04514029 2026-01-08
Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel
Masonic Cancer Center, University of Minnesota
Phase EARLY_PHASE1 Active not recruiting
NCT06514768 2026-01-06
JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase EARLY_PHASE1 Recruiting
NCT07205315 2025-12-26
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
Grit Biotechnology
Phase EARLY_PHASE1 Recruiting